[HTML][HTML] Initial confusion after massive Allerject recall
C Brown - 2015 - Can Med Assoc
Sanofi in Canada and the United States decided to recall the device, used for emergency
treatment of serious anaphylactic reactions, following 26 reports of suspected malfunction …
treatment of serious anaphylactic reactions, following 26 reports of suspected malfunction …
[HTML][HTML] Innovations in the treatment of anaphylaxis: a review of recent data
JA Lieberman, J Oppenheimer… - Annals of Allergy …, 2023 - Elsevier
Abstract Purpose of Review The current standard of first-line emergency treatment of
anaphylaxis is intramuscular (IM) epinephrine administered most commonly via epinephrine …
anaphylaxis is intramuscular (IM) epinephrine administered most commonly via epinephrine …
Reminder system for adrenaline autoinjectors does not work
NK Mülleneisen - Allergo Journal International, 2019 - Springer
It is well known that adherence to even written instructions for the use of adrenaline
autoinjectors (AAI) in case of anaphylaxis is bad [1]. Most patients do not always carry their …
autoinjectors (AAI) in case of anaphylaxis is bad [1]. Most patients do not always carry their …
Prevalence of biphasic response in anaphylaxis due to purposeful administration of allergenic food
Y Katz, A Nowak-Węgrzyn, JM Spergel - Annals of Allergy, Asthma & …, 2015 - annallergy.org
We have read with interest the article by Alqurashi et al 1 entitled “Epidemiological and
Clinical Predictors of Biphasic Reactions in Children With Anaphylaxis.” The authors report …
Clinical Predictors of Biphasic Reactions in Children With Anaphylaxis.” The authors report …
Correspondence to the “Guideline for acute therapy and management of anaphylaxis”
M Rudolph, M Fischer - Allergo journal international, 2015 - Springer
It was with great interest that we followed the updated version of the “Guideline for acute
therapy and management of anaphylaxis” published in the May issue of the Allergo Journal …
therapy and management of anaphylaxis” published in the May issue of the Allergo Journal …
Severe drug‐induced anaphylaxis: analysis of 333 cases recorded by the A llergy V igilance N etwork from 2002 to 2010
JM Renaudin, E Beaudouin, C Ponvert, P Demoly… - Allergy, 2013 - Wiley Online Library
Background A few series of well‐documented cases of severe drug‐induced anaphylaxis
(SDA) are available. Methods Cases collected by the A llergy V igilance N etwork from 2002 …
(SDA) are available. Methods Cases collected by the A llergy V igilance N etwork from 2002 …
[HTML][HTML] Crossing the threshold: can outcome data from food challenges be used to predict risk of anaphylaxis in the community?
PJ Turner, BK Wainstein - Allergy, 2017 - ncbi.nlm.nih.gov
There is increasing interest in using data from oral food challenges (OFC) performed under
medical supervision to assist in allergy risk management, both in industry (allergen risk …
medical supervision to assist in allergy risk management, both in industry (allergen risk …
[PDF][PDF] Adverse reactions to allergen injection: the Siriraj experience
C Bunnag - Siriraj Medical Journal, 2002 - researchgate.net
6l'lrflsl'l?I Page 1 6l'lrflsl'l?I STRIRAJ HOSPITAL GAZElTf, dotllil rrrliiBosrrdiio:$hlrritfi rrrDat
volume s4, Numbero, S€ptemb€r 2002 The Siriraj Experience llss cridc, r&n Janu,ry 1e37 'o …
volume s4, Numbero, S€ptemb€r 2002 The Siriraj Experience llss cridc, r&n Janu,ry 1e37 'o …
Everything you wanted to know about anaphylaxis, but were afraid to ask
M Greenhawt - Annals of Allergy, Asthma & Immunology, 2023 - annallergy.org
This issue of the Annals poses the challenge of “Everything you wanted to know about
anaphylaxis, but were afraid to ask.” The featured content takes a provocative look at …
anaphylaxis, but were afraid to ask.” The featured content takes a provocative look at …
Adverse drug reaction processing in the United States and its dependence on physician reporting: Zomepirac (Zomax®) as a case in point
KA Corre, TE Spielberg - Annals of emergency medicine, 1988 - Elsevier
Because of limited premarket testing for drugs newly approved by the FDA, serious but rare
side effects may not be apparent or publicized by the drug manufacturers. Therefore, only …
side effects may not be apparent or publicized by the drug manufacturers. Therefore, only …
